These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 39130753)

  • 1. Management of triple-negative breast cancer by natural compounds through different mechanistic pathways.
    Kaleem M; Thool M; Dumore NG; Abdulrahman AO; Ahmad W; Almostadi A; Alhashmi MH; Kamal MA; Tabrez S
    Front Genet; 2024; 15():1440430. PubMed ID: 39130753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetics of Triple-Negative Breast Cancer via Natural Compounds.
    Kaleem M; Perwaiz M; Nur SM; Abdulrahman AO; Ahmad W; Al-Abbasi FA; Kumar V; Kamal MA; Anwar F
    Curr Med Chem; 2022 Mar; 29(8):1436-1458. PubMed ID: 34238140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic Regulation and Dietary Control of Triple Negative Breast Cancer.
    Selmin OI; Donovan MG; Stillwater BJ; Neumayer L; Romagnolo DF
    Front Nutr; 2020; 7():159. PubMed ID: 33015128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential epigenetic modifications implicated in triple- to quadruple-negative breast cancer transition: a review.
    Muhammad A; Forcados GE; Katsayal BS; Bako RS; Aminu S; Sadiq IZ; Abubakar MB; Yusuf AP; Malami I; Faruk M; Ibrahim S; Pase PA; Ahmed S; Abubakar IB; Abubakar M; Yates C
    Epigenomics; 2022 Jun; 14(11):711-726. PubMed ID: 35473304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line.
    Dewi C; Fristiohady A; Amalia R; Khairul Ikram NK; Ibrahim S; Muchtaridi M
    Molecules; 2022 Jun; 27(12):. PubMed ID: 35744786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Insights into the Implication of Epigenetic Alterations in the EMT of Triple Negative Breast Cancer.
    Khaled N; Bidet Y
    Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 31003528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic modulations in triple-negative breast cancer: Therapeutic implications for tumor microenvironment.
    Zhou L; Yu CW
    Pharmacol Res; 2024 Jun; 204():107205. PubMed ID: 38719195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Triple-Negative Breast Cancer by the Phytopolyphenol Carnosol: ROS-Dependent Mechanisms.
    Alsamri H; Al Dhaheri Y; Iratni R
    Antioxidants (Basel); 2023 Jun; 12(7):. PubMed ID: 37507889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compounds from diverse natural origin against triple-negative breast cancer: A comprehensive review.
    Thilagavathi R; Priyankha S; Kannan M; Prakash M; Selvam C
    Chem Biol Drug Des; 2023 Jan; 101(1):218-243. PubMed ID: 36323650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of histone demethylases and histone methyltransferases in triple-negative breast cancer: Epigenetic mnemonics.
    Mandumpala JJ; Baby S; Tom AA; Godugu C; Shankaraiah N
    Life Sci; 2022 Mar; 292():120321. PubMed ID: 35031259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systems Medicine Design for Triple-Negative Breast Cancer and Non-Triple-Negative Breast Cancer Based on Systems Identification and Carcinogenic Mechanisms.
    Yeh SJ; Hsu BJ; Chen BS
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
    Su Y; Hopfinger NR; Nguyen TD; Pogash TJ; Santucci-Pereira J; Russo J
    J Exp Clin Cancer Res; 2018 Dec; 37(1):314. PubMed ID: 30547810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy.
    Yang R; Li Y; Wang H; Qin T; Yin X; Ma X
    Mol Biomed; 2022 Mar; 3(1):8. PubMed ID: 35243562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of Action.
    James N; Owusu E; Rivera G; Bandyopadhyay D
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic Reprogramming and Landscape of Transcriptomic Interactions: Impending Therapeutic Interference of Triple-Negative Breast Cancer in Molecular Medicine.
    Ray SK; Mukherjee S
    Curr Mol Med; 2022; 22(10):835-850. PubMed ID: 34872474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KMT2D-mediated H3K4me1 recruits YBX1 to facilitate triple-negative breast cancer progression through epigenetic activation of c-Myc.
    Yao B; Xing M; Zeng X; Zhang M; Zheng Q; Wang Z; Peng B; Qu S; Li L; Jin Y; Li H; Yuan H; Zhao Q; Ma C
    Clin Transl Med; 2024 Jul; 14(7):e1753. PubMed ID: 38967349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fat Biology in Triple-Negative Breast Cancer: Immune Regulation, Fibrosis, and Senescence.
    Lee CM; Fang S
    J Obes Metab Syndr; 2023 Dec; 32(4):312-321. PubMed ID: 38014425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Potential of Hormonal Therapies for Treatment of Triple-Negative Breast Cancer.
    Kirkby M; Popatia AM; Lavoie JR; Wang L
    Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer.
    Zhao Z; Li L; Du P; Ma L; Zhang W; Zheng L; Lan B; Zhang B; Ma F; Xu B; Zhan Q; Song Y
    Theranostics; 2019; 9(5):1401-1416. PubMed ID: 30867840
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.